Health Catalyst price target lowered to $2 from $5 at Canaccord

Canaccord analyst Richard Close lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $5 and keeps a Buy rating on the shares. The firm maintained its rating but acknowledged there is nothing to do right now until the company completes its strategic and operational reviews. The transition from DOS to Ignite is leading to the expectation of down-selling and potential customer attrition in some cases.